Advertisement
Research ArticleDrug Discovery and Translational Medicine

Pharmacological Characterization of AZD5069, a Slowly Reversible CXC Chemokine Receptor 2 Antagonist

David J. Nicholls, Katherine Wiley, Ian Dainty, Fraser MacIntosh, Caroline Phillips, Alasdair Gaw and Carina Kärrman Mårdh
Journal of Pharmacology and Experimental Therapeutics May 2015, 353 (2) 340-350; DOI: https://doi.org/10.1124/jpet.114.221358

Article Information

vol. 353 no. 2 340-350
DOI 
https://doi.org/10.1124/jpet.114.221358
PubMed 
25736418
Published By 
American Society for Pharmacology and Experimental Therapeutics
Print ISSN 
0022-3565
Online ISSN 
1521-0103
History 
  • Received November 10, 2014
  • Accepted February 27, 2015
  • Published online March 26, 2015.

Article Versions

Copyright & Usage 
Copyright © 2015 by The American Society for Pharmacology and Experimental Therapeutics

Author Information

  1. David J. Nicholls,
  2. Katherine Wiley1,
  3. Ian Dainty,
  4. Fraser MacIntosh2,
  5. Caroline Phillips,
  6. Alasdair Gaw3, and
  7. Carina Kärrman Mårdh
  1. Departments of Discovery Sciences (D.J.N.) and Oncology (C.P.), AstraZeneca R&D, Alderley Park, United Kingdom; Biosciences, AstraZeneca R&D Charnwood, Loughborough, Leicestershire, United Kingdom (K.W., F.M., A.G.); and Biosciences, AstraZeneca R&D, Mölndal, Sweden (I.D., C.K.M.)
  1. Address correspondence to:
    Carina Kärrman Mårdh, AstraZeneca R&D Mölndal, Pepparedsleden 1, Mölndal S-43183, Sweden. E-mail: carina.karrman-mardh{at}astrazeneca.com
View Full Text

Statistics from Altmetric.com

Article usage

Article usage: March 2015 to April 2022

AbstractFullPdf
Mar 201530112129
Apr 20152762663
May 20151501936
Jun 201567916
Jul 2015572426
Aug 2015452237
Sep 2015581325
Oct 2015431116
Nov 2015421316
Dec 2015401419
Jan 2016301625
Feb 2016291720
Mar 2016351223
Apr 2016172628
May 2016343535
Jun 2016395350
Jul 2016283141
Aug 2016343125
Sep 2016213229
Oct 2016143753
Nov 201674838
Dec 201623527
Jan 201727424
Feb 201725331
Mar 201736939
Apr 201744828
May 201796152
Jun 201735429
Jul 2017167658
Aug 201785671
Sep 201756657
Oct 201775352
Nov 2017117941
Dec 201795837
Jan 201844318
Feb 2018145365
Mar 2018145341
Apr 2018103930
May 201874353
Jun 2018114831
Jul 2018146146
Aug 201843427
Sep 201865537
Oct 201889138
Nov 201829047
Dec 201813624
Jan 201944338
Feb 201945260
Mar 201924439
Apr 201935743
May 201956860
Jun 201943630
Jul 201914934
Aug 2019215642
Sep 2019419739
Oct 201956371
Nov 201955042
Dec 201904122
Jan 202054428
Feb 202045127
Mar 202043922
Apr 2020105247
May 202055029
Jun 202034638
Jul 202044719
Aug 202023228
Sep 202083628
Oct 202074233
Nov 202086044
Dec 20201223541
Jan 202194441
Feb 202103948
Mar 2021115625
Apr 2021631019
May 20211101619
Jun 202167813
Jul 202150913
Aug 2021115816
Sep 2021541016
Oct 2021801318
Nov 202160911
Dec 20216358
Jan 202255731
Feb 202261521
Mar 202275928
Apr 20221411430

Back to top

In this issue

Download PDF
Article Alerts
Email Article
Citation Tools

Research ArticleDrug Discovery and Translational Medicine

Pharmacology of AZD5069, a CXCR2 Antagonist

David J. Nicholls, Katherine Wiley, Ian Dainty, Fraser MacIntosh, Caroline Phillips, Alasdair Gaw and Carina Kärrman Mårdh
Journal of Pharmacology and Experimental Therapeutics May 1, 2015, 353 (2) 340-350; DOI: https://doi.org/10.1124/jpet.114.221358
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo

Jump to section

Advertisement